Prostaglandins, leukotrienes, platelet-activating factor, lysophosphatidic acid, sphingosine 1-phosphate, and endocannabinoids, collectively referred to as lipid mediators, play pivotal roles in immune regulation and selfdefense, and in the maintenance of homeostasis in living systems. They are produced by multi-step enzymatic pathways, which are initiated by the de-esterification of membrane phospholipids by phospholipase A2s or sphingomyelinase. Lipid mediators exert their biological effects by binding to cognate receptors, which are members of the G protein-coupled receptor superfamily. The synthesis of the lipid mediators and subsequent induction of receptor activity is tightly regulated under normal physiological conditions, and enzyme and/or receptor dysfunction can lead to a variety of disease conditions. Thus, the manipulation of lipid mediator signaling, through either enzyme inhibitors or receptor antagonists and agonists, has great potential as a therapeutic approach to disease. In this review, I summarize our current state of knowledge of the synthesis of lipid mediators and the function of their cognate receptors, and discuss the effects of genetic or pharmacological ablation of enzyme or receptor function on various pathophysiological processes.
INTRODUCTION-OVERVIEW OF LIPID MEDIATORS
Lipids are the major constituents of the cellular membranes of all organisms. Due to the amphipathic properties of lipid molecules, the structure of all cellular membranes is a bimolecular leaflet, termed the lipid bilayer (1, 2) . Lipids are the most efficient source of energy for living organisms, and excess storage or decreased lipid usage results in energy imbalance and can lead to the development of metabolic syndromes (3) . Certain lipid moieties are also covalently or noncovalently linked to proteins, a post-translational modification that facilitates many types of protein-protein or lipid-protein interactions (4) . Lipid molecules also function directly as intercellular signaling molecules in immune self-defense and the maintenance of homeostasis (5, 6) . Prostaglandins (PGs), leukotrienes (LTs), lipoxins (LXs), hydroxy fatty acids (eicosanoids), platelet-activating factor (PAF), lysophosphatidic acid (LPA), sphingosine 1-phosphate (S1P), and 2-arachidonoylglycerol, as well as others, are collectively referred to as lipid mediators.
In concert with other types of signaling molecules, such as neurotransmitters, hormones, and cytokines, lipid mediators are shown to play important roles in the regulation of cell proliferation and differentiation, as well as the reproductive, gastrointestinal, and cardiovascular systems. They also play a fundamental role in inflammatory and immune responses. Lipid mediators have several characteristics that distinguish them from other signaling molecules. They are synthesized on-demand in a calcium-dependent manner from precursor membrane lipids.
With some exceptions, they have a relatively short half-life (seconds to minutes), and can be degraded both enzymatically and nonenzymatically. Finally, they act on class I G protein-coupled receptors (GPCRs). In this chapter, I summarize the production mechanisms of lipid mediators, and the biological effects of lipid mediator binding to cognate GPCRs. I also explore how disruption of the coordinated action of lipid mediators and their receptors can result in disease. Table 1 presents a summary of the classification of lipid mediators and a brief description of their biological activities. Figure 1 shows the structures of representative lipid mediators from each class. Because of space limitations, I focus this review primarily on the eicosanoids (e.g. PGs, LTs,HETEs and lipoxins) as well as PAF, but I briefly discuss, where relevant, other lipid mediators as well.
Azelaoyl PC Platelet-activating factor (PAF)
O
ENZYMES INVOLVED IN THE BIOSYNTHESIS OF EICOSANOIDS AND PAF

Phospholipase A2
When cells or tissues are exposed to physiological and pathological stimuli, glycerophospholipids are hydrolized and converted to two products; arachidonic acid (or polyunsaturated fatty acid) and lysophopholipids by the action of phospholipase A2 (PLA2) (7) (8) (9) . Lysophopholipids function as signaling molecules, or serve as precursors of other lysophospholipid mediators (see below)
( Figure 2 ). There are more than 20 different PLA2s in mammals. They are classified into four categories on the basis of their molecular structure and biochemical properties. Secretory PLA2s (sPLA2s) comprise proteins of approximately 20 kD that contain multiple disulfide (S-S) bonds (10, 11) . These are stimulated by mM concentrations of Ca 2+ , and their function is primarily extracellular. Cytosolic PLA2s (cPLA2s) are present in the cytosol, and are activated by μM concentrations of Ca 2+ and protein serine/threonine kinases (12, 13) . Calcium is not required for the catalytic activity of cPLA2s, but it is important for the interaction of this group of enzymes with the phospholipid membrane. There are six different cPLA2s (Figure 3) , of which cPLA2α (Group IVA PLA2) has been shown to be a pivotal enzyme in the production of eicosanoids and PAF (14) (15) (16) . The third category comprises the Ca-independent PLA2s (iPLA2s), which also localize to the cytosol (17) (18) (19) . Although the precise function of the iPLA2s remains elusive, they are implicated in tissue developments and hormone secretion. The fourth category of PLA2s comprises the PAF acetylhydrolases, which inactivate PAF and oxidized phospholipids to yield lysophospholipids (20) (21) (22) . There are at least three enzymes in this class: two are cytosolic enzymes and the third is present in plasma and tissue fluids. One of the cytosolic acetylhydrolases has a trimeric structure, consisting of α1, α2, and β subunits, and has been the subject of much recent attention, as the β subunit is identical to the human lissencephaly gene (LIS-1), the causative gene of Miller-Dieker syndrome (23) .
Acyl-CoA: Lysophospholipid Acyltransferase
Lysophospholipids (derived from lysis) are cytotoxic at high concentrations, and if they are not secreted or metabolized into PAF or other types of lipid mediators, they are typically converted into glycerophospholipids. The incorporation of poly-unsaturated fatty acids at the sn-2 position of glycerophospholipids is catalyzed by acyl-CoA:lysophospholipid acyltransferases (simply termed acyltransferases). The asymmetrical distribution of saturated or monounsaturated fatty acids at the sn-1 position and polyunsaturated fatty acids at the sn-2 position is maintained in part by a deacylation-reacylation process first proposed by William E. Lands in the late 1950s (the Lands' cycle, or Kennedy independent cycle) (24) (25) (26) (27) . Several members of the acyltransferase family have been recently identified by our laboratory and others, and shown to possess broad and somewhat overlapped substrate specificities that are dependent on their tissue distribution and external stimuli (28) (29) (30) (31) (32) (33) (34) (35) . Thus, acyltransferases have emerged as a potential key to the diversity of membrane phospholipids. Figure 4 shows a scheme of the putative acyltransferase family members (36) . A more detailed discussion of the properties of individual enzymes can be found in several previously published reviews (29, 192) .
Acetyl-CoA:lyso-PAF Acetyltransferase
As illustrated in Figure 2 , lysophospholipids with an alkyl-ether bond at the sn-1 position are converted to PAF by the activity of an acetyltransferase. Although a number of pioneering efforts to characterize the acetyltransferase involved in this process have been reported, there has been limited success in cloning the gene, primarily because the protein is membrane-spanning and highly unstable (37) (38) (39) (40) . Shindou et al. (41, 42) examined the regulation mechanism of this acetyltransferase in 2005.They demonstrated that it is induced by lipopolysaccharide (LPS) at 10-20 hours after stimulation, and exhibits a biphasic pattern of activation, with activation on the order of minutes (min) by PAF, possibly through the mobilization of intracellular Ca 2+ stores. At approximately 30 min, activation is regulated by LPS through p38 kinase (42) . Our laboratoryrecently isolated a member of the acetyltransferase gene family (LysoPAFAT/LPCAT2) that Biosynthetic pathways of eicosanoids and platelet-activating factor (PAF). Enzyme names are also described: 15-PGDH, 15-hydroxy-PG dehydrogenase; PGD(E, F)S, PGD (E, F) synthase; TXAS, TX synthase; 5-LO, 5-lipoxygenase. Lysophospholipid acyltransferase gene superfamily.
is highly expressed in inflammatory cells (43) . The enzyme is a 60 Kd protein with three putative membrane-spanning domains, several EF-hand motifs, and a C-terminal endoplasmic reticulum (ER) retention sequence. The properties of the enzyme (induction and activation) were similar to the previously published data of Shindou et al. (42) . Quite unexpectedly, however, the enzyme also possessed lysophosphatidylcholine (LPC) acyltransferase activity, catalyzing the incorporation of arachidonoyl-CoA into LPC (or its alkyl ether analogue) to produce membrane PC derivatives (43 ( Figure 5 ). Other types of PAF biosynthetic enzymes display constitutive activity and do not require Ca 2+ , such as LPCAT1 (44) . As potential targets of anti-inflammatory drugs, the inducible lysoPAF acetyltransferases (such as LysoPAFAT/LPCAT2) are excellent candidatesbecause the inhibition of this family of enzymes can potentially inhibit the proliferation of inflammatory cells through the disruption of membrane biogenesis without affecting the physiological function of PAF.
Cyclooxygenases and Lipoxygenases
Cyclooxygenase (Cox) catalyzes the incorporation of two oxygen molecules into arachidonic acid to form PG endoperoxides, which are converted into various types of PGs, depending on the type of cell or tissue, by terminal PG synthases (Figure 2) . Two Cox isoenzymes have been identified: a constitutive form, Cox-1, and an inducible form, Cox-2 (45, 46) . Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit the activity of both enzymes through the acetylation of Ser residues near the catalytic pocket. Cox enzymes are present in the ER and nuclear membrane, and form homodimers. The induction of Cox-2 expression is regulated by at least three independent mechanisms: 1. transcriptional regulation through nuclear factor-kappa B (NF-κB) and cAMP response element binding protein (CREB); 2. mRNA stabilization through the proximal AT-rich sequence of the 3'-untranslated region; 3. the expression of microRNAs. Nonselective Cox inhibitors (such as the NSAIDs) are widely used in the treatment of inflammatory disorders and the prevention of thrombosis. They also have been explored as potential therapeutics in the prevention and treatment of colon cancer (47) and Alzheimer's disease (48) . Cox-2 selective inhibitors, developed primarily by three pharmaceutical companies, have become globally distributed blockbuster drugs because of their decreased gastrointestinal side effects. However, the use of selective Cox-2 inhibitors has recently come under close scrutiny because of the association of these drugs with adverse cardiovascular effects (49) , although the association remains controversial (50, 51) . The cause of the cardiovascular side effects is not clear, but appears to involve the inhibition of prostacyclin (PGI2) formation and plaque destablization (52) (53) (54) . The antipyretic and analgesic functions of acetoaminophene are not fully understood.
In mammals, the six different types of lipoxygenase are named according to the carbon position at which a single oxygen molecule is incorporated: 5-lipoxygenase, 8/12-lipoxygenase, two types of 12-lipoxygenase (12S-lipoxygease and 12R-lipoxygenase), and two types of 15-lipoxygenase (55) . Among them, 5-lipoxygenase has been the most extensively studied (56). 5-Lipoxygenase catalyzes two sequential reactions, the incorporation of oxygen at the C-5 position, and subsequent dehydration to produce an allylic epoxide, LTA4 (57) (58) (59) (60) (61) . LTA4 is then converted to LTB4 by LTA4 hydrolase (62) (63) (64) (65) (66) , or to a cysteinyl-LT (such as LTC4, LTD4, or LTE4) by LTC4 synthase (67-69) (Figure 2 ). LTB4 is a potent chemoattractant and regulator of immune responses, whereas cysteinyl-LTs are a major component of the inflammatory agent slow reacting substance of anaphylaxis (SRS-A) (56, 70) . The activity of 5-lipoxygenase is calcium dependentand regulated by multiple kinases. Like cPLA2α (71), 5-lipoxygenase translocates to the perinuclear membrane in response to changes in Ca 2+ levels in the cytoplasm or nucleoplasm (72, 73) . Five lipoxygenase activating proteins (FLAP) are present at the perinuclear membrane, and may be involved in the coupling of cPLA2α and 5-lipoxygenase activity by functioning as scaffolding proteins (74, 75) . Scaffolding proteins such as FLAP have been proposed as mechanisms for the efficient production of eicosanoids and other lipid mediators by assembling multi-component signaling complexes. Although many enzymes are involved in the catalysis of lipid mediators, only 5-lipoxygenase inhibitors are currently approved for clinical use. Other inhibitors are in preclinical or clinical trials, and FLAP inhibitors appear promising. A group of alternative products of the lipoxygenase pathway, the lipoxins, resolvins, and neuroprotectins, has recently been described (76) (77) (78) (79) (80) . The synthesis of these lipid mediators involves highly unsaturated fatty acids as substrates, such as eicosapentaenoic acid and docosahexaenoic acids, and utilizes more than two different lipoxygenases (81) (82) (83) . Of note, members of this group of compounds appear to have anti-inflammatory or preresolution properties.
Other Enzymes
LPA is produced from LPC by the action of lysophospholipase D (84) (85) (86) (87) . Lysophospholipase D is a secretory protein found in plasma (88) and is identical to autotaxin, a chemotactic protein (89) . Sphingosine kinases (types 1, 2) convert sphingosine to S1P (90) (91) (92) . In addition to the enzymes involved in synthesis, all lipid mediators are subject to enzymatic degradation. PG is converted to 15-keto-PG by 15-hydroxy-PG dehydrogenases in the presence of NAD+ or NADP+. LTB4 is inactivated by ω-oxidation or oxidation of the 12(R)-hydroxy moiety (93) . The half-life of the eicosanoids is typically on the order of seconds (sec) to min, thus they are referred to as local mediators. By comparison, LPA and S1P have relatively long half-lives (min to hours) in vivo, and their levels are maintained in plasma in the μM and 10 nM concentration range, respectively.
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G PROTEIN-COUPLED RECEPTORS FOR LIPID MEDIATORS
In humans, nearly 350 different nonolfactory GPCRs are identified (94) . In 1991, our laboratory was the first to report the successful cloning of a lipid GPCR, the PAF receptor, using expression cloning in Xenopus oocytes and electrophysiology (95) . Since that time, several lipid GPCRs have been identified and characterized; nine different PG receptors and four distinct LT receptors have been reported. The endothelial differentiation gene (Edg) family consists of 3 LPA receptors (LPA1-3) and 5 S1P receptors (S1P1-5). Members of this family are 40% homologous to the endocannabinoid receptors, CB1 and CB2. As of the writing of this review, more than 30 lipid GPCRs have been identified (Figure 6 ). Certain families of lipid GPCRs appear, because of the structural similarity of their ligands, to have evolved from the same ancestor (e.g., the PG and Edg receptor families), whereas other lipid GPCR families are evolved on the basis of functional similarity. For example, the LTB4 receptors BLT1 and BLT2 are evolutionarily distant from Phylogenetic tree of Lipid G protein-coupled receptors (GPCRs) and orphan receptors.
the PG or cysteinyl-LT receptors (CysLT1 and CysLT2), but in the same family as the Gicoupled chemoattractant receptors, which also includes receptors for lipoxins, formyl-peptides, and complement (C5a, C3a). Most lipid GPCRs are relatively compact in size, comprising 300-400 amino acid residues.
Prostaglandin Receptors
PGs mediate a variety of biological functions in almost all tissues through the activation of their cognate receptors (96) (97) (98) . The thromboxane (Tx) receptor (TP) was cloned in 1991 and has the structure of a typical GPCR. On the basis of homology with TP, seven additional PG receptors in various species have been identified. These include the PGD receptor (DP), PGE receptor (EP1-4), PGF receptor (FP) and PGI2 receptor (IP). These receptors have similar structural features, including PG receptor-specific consensus motifs in the seventh transmembrane domain and the second and third intracellular domains, as well as consensus amino acid sequences that are conserved in most class I GPCRs. Alternative splicing of human TP, EP3, and FP results in isoforms that have different C-terminal domains, but there are no significant differences in the ligand binding and intracellular signaling properties of the various isoforms. The eight PG receptors identified to date are classified into four subfamilies according to structural and functional similarity. The EP1-FP-TP subfamily mediates the mobilization of cytosolic Ca 2+ (termed contractile receptors), andthe EP2-EP4-IP-DP subfamily mediates the production of cyclic AMP (termed relaxant receptors) (96) . The activation of EP3 results in a decrease in cyclic AMP production; hence, this receptor is classified an inhibitory receptor. A second type of PGD receptor, CRTH2 or DP2, belongs to the family of chemoattractant receptors like BLT1 and BLT2. In contrast to DP (DP1), CRTH2 exhibits broad specificity for a variety of ligands, including PGD2, 15-keto-PGD2 (inactive for DP1), and indomethacin (99) . Similar to other chemoattractant receptors, CRTH2/DP2 mediates chemotaxis in eosinophils and lymphocytes through the activation of Gi.
Leukotriene Receptors
LTB4 is a one of the most potent chemotactic compounds for neutrophils, eosinophils and macrophages. In addition, recent studies have revealed that it plays a role in immune regulation. In our laboratory, we have cloned two types of LTB4 receptors, BLT1 and BLT2, using subtraction techniques and homology screening, respectively. BLT1 and BLT2 are members of the chemoattractant receptor family (100-102) (Figure 6) . Originally, we reported that BLT2 is a low-affinity receptor for LTB4 and other hydroxy-eicosanoids (HETEs). However, we subsequently identified 12-hydroxy-heptadecatrienoic acid (12-HHT), a cyclooxygenase product, as a natural, high-affinity ligand for BLT2 by screening lipid fractions from mouse tissue extracts (103). 12-HHT is produced in equimolar amounts with TXA2 from PGH2 by thromboxane synthase. It can also be produced nonenzymatically from PGH2, particularly in the presence of heme and glutathione. In vivo, 12-HHT induced chemotaxis in mast cells through the activation of BLT2. On the basis of these results, we propose that BLT2 be now referred to as BLT2/HHTR. Additionally, two cysteinyl-LT receptors are members of the lipid/nucleotide receptor family: CysLT1, a high-affinity LTD4 receptor (104, 105) , and CysLT2, a low affinity receptor for LTC4 and LTD4 (106, 107) (Figure 6 ). The activation of CysLT1 results in bronchoconstriction and increased vascular permeability, however, the biological role and natural ligands for CysLT2 remain to be elucidated. BLT1, BLT2/HHTR, and CysLT1 mediate Ca 2+ mobilization and the inhibition of adenylate cyclase, whereas CysLT2 mediates Ca 2+ mobilization and increased cyclic AMP levels.
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PAF Receptor
PAF was originally identified as a hypotensive agent and platelet-activating mediator. It was subsequently shown to have versatile biological activities in almost all tissues. We have cloned PAF receptors from guinea pig, mouse, rat, and human (95, 108) . Similar to PG and LT receptors, PAF receptors are relatively small-sized GPCRs. Two different PAF receptor mRNAs are generated by the use of alternative promoters. The expression of transcript I is regulated by estrogen and other hormones, whereas transcript II is regulated by the PKC-NFκB pathway. Transcripts I and II are expressed in different tissues, but their open reading frames are identical. The PAF receptor (PAFR) binds to PAF, as well as oxidized phospholipids, lysoPC, and lipopolysaccharide at higher concentrations, and is coupled to G proteins Gi, Gq, and G12/13. Activation of PAFR results in the inhibition of cyclic AMP formation, mobilization of intracellular Ca 2+ , and the activation of mitogen-activated protein kinases. Thus, it appears that PAFR engages a variety of intracellular signaling pathways, which helps explain its wide range of biological functions. Additional information on PAFR activity and function can be found in reviews 109 and 110.
Lysophospholipid Receptors
Lysophospholipids, such as LPA and S1P, are membrane-derived lipid mediators. They are involved in the regulation of fundamental cellular responses, including cell proliferation, differentiation, migration, adhesion and morphogenesis. There are five different LPA receptors (LPA1-5) (111, 112), and a sixth, p2y5, a relative of p2y9/GPR23/LPA4 (56% homology), has recently been proposed. LPA1, LPA2 and LPA3 are Edg-family members, and are 50-60% homologous to each other, whereas LPA4 and LPA5, and possibly LPA6 (p2y5), form a distinct family (Figure 6 ). The two families of LPA receptors differ in their G protein specificity and tissue distribution, which might explain the broad range of functions of LPA. It is noteworthy that human genetic hair anomaly is associated with mutation of p2y5 (113, 114) . At present, five different S1P receptors (S1P1-5) are identified, all of which are Edg-family members. In contrast to PG receptors, the lysophospholipid receptors appear to be less heterogenous, with similar G protein specificities and a ubiquitous pattern of expression. Additional information on lysophospholipid receptors is available in several other current reviews (115-119).
Other Lipid GPCRs
The cannabinoid receptors CB1 and CB2 are GPCRs that also interact with lipid ligands (120) . CB1 is expressed primarily in the central nervous system and is involved in the regulation of GABAergic neurons (121, 122) , whereas CB2 is expressed primarily in immune cells (123) . Although not described in this review, several other lipid ligands (i.e., bile acids, short-chain fatty acids, lysophosphatidylserine, and lysophophatidylinositol) are reported to bind to cognate GPCRs (Figure 6 ). It also has been suggested that the proton-sensing GPCRs G2A, TDAG8, OGR1, and GPR4 interact either directly or indirectly with lipid molecules (124) , but additional studies are needed to understand the significance of these lipid-GPCR interactions. In our laboratory, we are screening lipid ligands from tissue extracts in an effort to identify novel lipid mediators of orphan receptors.
Nuclear Receptors
There are reports that lipid mediators can bind to nuclear receptors (NRs), particularly the peroxisome-proliferator activator receptor (PPAR) family of NRs. PGJ2 derivatives (125, 126) , PGI2, PAF, LPA (127) , and long chain fatty acids have all been implicated in binding to PPARs. Although these observations are consistent with the production site of most lipid mediators, in the perinuclear or nuclear membrane, PPARs have spacious binding pockets and the in vivo biological significance of these interactions is yet to be determined.
LIPID MEDIATORS IN HEALTH AND DISEASES
Lipid mediators were historically considered terminal mediators, causing symptoms such as fever, pain, edema, smooth muscle contraction, and inflammation. However, recent studies using gene knockout mice (for both enzymes and receptors) have revealed that lipid mediators play a much more fundamental role in normal physiological processes and in disease. A discussion of the pathophysiological roles of all the various classes of lipid mediators is beyond the scope of a single review, and excellent review articles that describe the phenotypes of specific gene knockout mice, particularly the receptor knockout mice, are currently available (97, 116) . The remainder of this review is focused on the phenotype of mice carrying a deletion of cPLA2α, an enzyme that is either fully or partially involved in the production of various lipid mediators. I also examine the molecular mechanisms of cPLA2α function by comparing cPLA2α knockout mice to knockout mice in which downstream enzymes or individual receptors are targeted. Lastly, I explore how a comprehensive lipidomics approach to analyzing downstream lipid mediators using liquid chromatography-tandem mass spectrometry (LC-MS/MS) can offer valuable insight into the role of lipid mediators in health and human disease.
Phenotype of cPLA2α Knockout mice
Subsequent to the discovery of cPLA2α in 1991 by Clark et al. (128) and Kramer et al. (12), we and others established cPLA2α knockout mice (129, 130) , and backcrossed the knockout mice with a variety of mouse strains (C57/Bl6, C3HeN, C3HeJ, DBA, Balb/c, etc). In our original report, we demonstrated that cPLA2α is essential for the production of various types of eicosanoids and PAF in peritoneal and alveolar macrophages (129) . Table 2 summarizes the phenotypes of cPLA2α 
Physiology and Pathology References Physiological abnormality
Reproduction failure (129, 130, 132) Renal physiology failure (175) Change in brain lipid composition (176) Protection from disease models:
Ischemia-reperfusion injury (130, 177) MPTP-induced neurotoxicity (178, 179) Experimental allergic encephalomyelitis (EAE)
Ovalbumin-induced anaphylaxis and bronchial asthma (129, 181, 182) Thrombosis and platelet functions (183) Acute respiratory distress syndrome (ARDS) (184, 185) Bleomycin-induced lung fibrosis (157) Collagen-induced arthritis (139) Inflammatory bone resorption (186) Intestinal polyposis (137, 187) Parasite and bacterial infection (188) (189) (190) Type I diabetes mellitus (191) knockout mice generated by others and us (131) . cPLA2α-null mice are born in the expected Mendelian ratio, and appear to be healthy, with the exception of multiple small intestinal ulcers. This is consistent with a reported case of human cPLA2α-deficiency, in which individuals exhibit a bleeding tendency and intestinal ulcers (193) . In cPLA2α knockout mice, routine biochemical and immunological parameters of the serum are in the normal range, and the life span appears normal. However, knockout mice exhibit abnormalities in synaptic plasticity and reproduction (implantation and labor), and exhibit much milder symptoms in a number of disease models. The mice are protected from anaphylactic symptoms, bronchial asthma, brain injury in response to multiple stimuli, thrombosis, collagen-induced arthritis (a model for rheumatoid arthritis), endotoxin-induced bone resorption, bleomycin-induced lung fibrosis, and experimental allergic encephalomyelitis (a model for multiple sclerosis).
Comparison with the Phenotypes of other Knockout Mice
In this section, I compare the phenotypes of cPLA2α-deficient mice with other knockout mice, highlighting points of consensus and controversy.
Reproduction
When cPLA2α-null mice are born, they appear normal. However, when wild-type male mice are mated with cPLA2α-null female mice, there is an obvious reduction in the number of offspring (129) . Implantation in knockout mice is severely impaired, and labor does not commence at term. Similar cPLA2α-null phenotypes have been reported by others (130, 132) , who have proposed that the implantation defect of cPLA2α-null mice involves a deficiency of PGI2. Cox-1-or 5-lipoxygenase-null mice do not exhibit the implantation phenotype. Cox-2-null mice exhibit multiple abnormalities, including defects in ovulation, fertilization, implantation, and embryogenesis (133) . It was recently reported that LPA3-null mice exhibit implantation failure owing to the lack of Cox-2 expression in the uterus, and that the defect is rescued by the administration of either a stable PGI2 analogue or PGE2 (134) . However, the mechanism of implantation failure in cPLA2α-null mice remains controversial, as IP (PGI2 receptor)-null or EP-null mice do not exhibit this phenotype. Furthermore, several groups have reported that Cox-2-null mice do not exhibit such severe abnormalities in reproduction (135) . Additional studies are needed to explore the nature of these apparent contradictions among various groups of mice. The labor phenotype of cPLA2α knockout mice is due primarily to the loss of PGF2α. During periparturition, the expression of Cox-2 is induced, and the induction of luteolysis by PGF2α results in increased oxytocin receptor levels and decreased serum progesterone levels by luteolysis. FP-null mice exhibit a similar phenotype, and labor loss in both cPLA2α and FP knockout mice is rescued by the administration of a progesterone antagonist or ovariectomy at embryonic day 19 (136) . Although the precise mechanism of the labor loss phenotype of cPLA2α-null mice remains obscure, cPLA2α inhibitors, such as NSAIDs, are contraindicated in pregnancy, and in women who can become pregnant.
Intestinal Polyposis
Deletion of Cox-2 or the use of Cox-2 selective inhibitors causes a reduction in polyp number and size in APC(716) mice, an animal model of familial adenomatous polyposis. A similar effect is observed in EP2-null mice. The expression of cPLA2α, Cox-2, and EP2 is upregulated in polyp tissue as compared with adjacent normal epithelium in APC (716) both western blot and reverse-transcription PCR analysis. cPLA2α-null mice exhibit a relatively mild phenotype in terms of tumor size, particularly in the small intestine, which might be a result of the presence of other, compensatory, PLA2 isoforms (i.e., type X sPLA2) in the colon (137) . The current hypothesis of tumor development in APC(716) mice is as follows: PGE2 is produced through the action of cPLA2α and Cox-2 (135), and possibly microsomal PGE synthase type 1. PGE2 binds to its cognate receptor, EP2, and induces cyclic AMP production and the activation of protein kinase A (138). Protein kinase A induces the expression of Cox-2 through binding of cyclic AMP response element (CRE) binding protein to CRE of the Cox-2 gene promoter, resulting in further elevation in PGE2 levels. The CRE-dependent induction of vascular endothelial growth factor (VEGF) and matrix metalloproteinases also promotes cell growth and cell invasion. Inhibitors of Cox-2, cPLA2α, or EP2 receptor antagonists effective in terminating polyp growth are the most likely candidates for preventing colon cancer.
Rheumatoid Arthritis
cPLA2α-null mice are resistant to collagen-induced arthritis, and their clinical scores are equally good (1 or lower during the experimental period of observation) as those of TNFα-null mice (139) . Cox-2-null mice (140) and microsomal PGE synthase-null mice also exhibit a similar phenotype. Recently, genetic ablation of BLT1 (141, 142) , DP, or IP (143) protected mice from developing arthritis, although the roles of individual mediators may be different. In most reports, the production of inflammatory cytokines, such as TNFα, interleukin 1, and interleukin 6, was decreased in synovial cells, and T-cell infiltration of the joint tissues was apparent. These observations are difficult to interpret, but it seems likely that the inhibition of cPLA2α would suppress all of these lipid mediators. However, the relationship between cytokines, chemokines, and lipid mediators certainly warrants further investigation.
Multiple Sclerosis
Experimental autoimmune (allergic) encephalomyelitis (EAE) is a Th1-type autoimmune disorder, characterized by demyelination and inflammation. cPLA2α-null mice are completely resistant to myelin oligodendrocyte glycoprotein (MOG)-induced EAE, an animal model of multiple sclerosis (MS). Using a comprehensive lipidomics approach, we have determined the various lipid mediators of the spinal cord in the disease processes are: naïve, induction, acute, and chronic. We found that Cox products are increased in early stages of the disease (induction phase to acute phase), whereas PAF is produced in the later, chronic phase. Genetic and pharmacological inhibition of Cox-2 prevent onset and progression of EAE (144, 145) . The products of 5-lipoxygenase are decreased in all stages. These results are consistent with previous reports of PAFR-null mice, which exhibit milder symptoms during later phases of disease progression (the T-cell independent phase) (146), and 5-lipoxygensae-null mice, which exhibit a more severe phenotype than the littermate wild type mice (147) . It remains to be determined which Cox products and which receptors initiate disease onset and progression, and the mechanism of protection from disease by the products of 5-lipoxygenase.
Bronchial Asthma
Bronchial asthma is a Th2-type immune disorder, characterized by inflammatory cell migration, airway hypersensitivity, and remodeling of the bronchoalveolar structures (148) . Experimentally, bronchial asthma can be induced in animals by sensitization with ovalbumin or house dust with adjuvants. When cPLA2-null mice are exposed to an antigen to induce bronchial asthma, the (129) . BLT1-null mice are also protected from these symptoms, through a mechanism involving the inhibition of early T-cell recruitment (both CD4+ and cytotoxic CD8+) and eosinophil infiltration (149) (150) (151) (152) (153) (154) (155) . The levels of IgE, IgG1, and Th2 cytokines in plasma and bronchoalveolar lavage fluids differ depending on the immunization protocol. Compared with wild-type mice, LTC4 synthase-null mice or CysLT1-null mice exhibit attenuated airway hyperreactivity, decreased OVA-specific IgE production, and decreased eosinophil infiltration (156) , whereas PAFR-null mice exhibit decreased airway hyperreactivity without corresponding changes in cellular infiltration and cytokine production (109) . The roles of BLT2 and CysLT2 in this model remain elusive.
Pulmonary Fibrosis
Pulmonary fibrosis in cPLA2α-null mice was induced by multiple intraperitoneal injections of bleomycin. Cysteinyl-LTs were elevated in lung lavage fluid in the mice (157) . In 5-lipoxygenasenull mice, the induction of pulmonary fibrosis resulted in milder lung pathology and lower hydroxyproline levels than wild-type mice, similar to cPLA2α-null mice (158) . In Cox-2-null mice, pulmonary dysfunction was exacerbated, with no accompanying changes in collagen content or lung histology (159) . Cox-1 overproduction in these mice was reported, which may partially compensate for the Cox-2 defect. In addition, the authors proposed that granulocyte-macrophage colony-stimulating factor (GM-CSF) enhances the production of PGE2, which has antifibrotic properties, whereas TGFβ induces profibrotic 5-lipoxygenase products (158) . There have been several interesting and challenging reports of pulmonary fibrosis in CysLT1-, CysLT2-and LTC4 synthase-null mice. Although genetic ablation of LTC4 synthase attenuated lung fibrosis, CysLT1-null mice exhibited a more severe phenotype of fibrotic damage in the lung than the wild type (160). However, CysLT2-null mice were protected from fibrosis (161) . The underlying mechanisms of these phenotypes are yet unknown, but the authors demonstrated that cysteinyl-LT was elevated in CysLT1-null mice, but not in CysLT2-null mice (160). Izumo et al. (162) reported that, on the bases of Aschcroft score, hydroxyproline content, and TGF-β levels, pharmacological inhibition of CysLT1 using Montelukast attenuates lung fibrosis. Additional studies and integrated analyses are needed to elucidate the roles of lipid mediators in the onset and development of pulmonary fibrosis. In this regard, it was recently reported that LPA1-null mice also exhibit attenuated lung fibrosis (163) , and it was proposed that LPA1 antagonists may be of benefit in the prevention or treatment of lung fibrosis.
Others
Because of the scope of this review, I have omitted discussions of many other important findings related to lipid mediators in health and diseases. However, one prominent issue worth mentioning is the role of S1P in the immune response and embryogenesis. A potent S1P1 agonist (a functional antagonist because it elicits receptor internalization), FTY720 (a prodrug, only active after phosphorylation by sphingosine kinases), is currently undergoing clinical trials as an immunosuppressive drug for organ transplantation and MS. FTY720 dramatically decreases the number of circulating lymphocytes in the body by inhibiting the emigration of lymphocytes from local lymph nodes (164) (165) (166) (167) (168) . The drug also shows adverse side effects including bradycardia. S1P1-null mice exhibit embryonic lethality at embryonic day 10 because of a lack of vasculogenesis (169), and LPA receptor double-and triple-knockout mice exhibit morphological and developmental abnormalities in the brain. The genetic ablation of autotaxin (lysophospholipase D) in mice results in similar phenotypes to S1P1-null mice (170, 171) , and is also an embryonic lethal mutation. This is somewhat surprising, because lysophospholipase D is not involved in the production of S1P in vivo, and none of the double-or triple knockout mice of LPA receptors exhibit such lethal abnormality.
Comprehensive Analyses of Eicosanoids and PAF by LC-MS/MS
A potentially valuable and promising approach to understanding the molecular basis of the cPLA2α-null phenotypes in various disease states is the identification of specific downstream lipid mediators and the time course of their activity. Our laboratory is currently engaged in a systematic quantification of specific lipid mediators involved in human diseases, with the goal of using this information as a diagnostic and prognostic tool, and as a guide for future studies. Through a comprehensive, top-down profiling of lipid mediators, one can arrive at a better understanding of the roles of individual mediators. We have established a sensitive and highly selective method of measuring 14-20 different lipid mediators in a single sample within 10 min (172, 173) . Supplemental Figure 1a (follow the Supplemental Material link from the Annual Reviews home page at http://www.annualreviews.org) is a typical chromatogram result, demonstrating that we can detect 14 different lipid mediators downstream of cPLA2α. Using peritoneal macrophages, it is clear that PGs are produced rapidly, whereas LTs are produced more slowly and are less labile. PAF is produced rapidly, but is also degraded quickly by PAF acetylhydrolases present in plasma and macrophages (Supplemental Figure 1b) .
Application of the Methods for Disease Models
I present the results of lipid profiling in two animal models of brain disease, kainate-induced seizures and experimental allergic encephalomyelitis, to illustrate the utility of this comprehensive lipidomics approach. In animals of various species, kainic acid (KA) induces seizures accompanied by the production of eicosanoids. In our laboratory, we profiled eicosanoids in the hippocampus and cerebral cortex at various times after the application of KA using LC-MS/MS (174) . KA induced robust production of PGF2α and PGD2 in the hippocampus, and a relatively smaller level of production of other PGs and HETEs. LT was undetectable in the brain following KA stimulation. The production of eicosanoids was biphasic, with peaks of production within 30 min, and again at 16-24 hours, and was limited initially to the hippocampus. Cox-2 selective inhibitors abrogated the early production of mediators, with the exception of TXB2 and PGD2, which suggests that the latter two compounds are produced predominantly by Cox-1. The sustained production of PGs during the late phase in the brain appeared a result of notable induction of Cox-2, despite the limited supply of arachidonic acid by PLA2. The sustained production of PGs was not caused by cPLA2α, as cPLA2α-null mice exhibited a similar profile (Y. Kita & K. Yoshikawa, unpublished data). Although this study was not aimed at addressing the function of eicosanoids in epileptic seizures or neuronal degeneration, these results reveal that PG production is biphasic, which is an important consideration in developing treatments. Furthermore, the role of NSAIDs in the prevention or aggravation of seizure symptoms and neuronal cell death is controversial. In most studies that examine this issue, animals are pretreated with NSAIDs, likely inhibiting only the initial phase of PG production. However, the roles of the PGs produced in the early and late phases might be different, and further studies are necessary to determine the optimal type of Cox inhibitor(s) and time point for intervention to prevent cell death and promote cell recovery. In a second study, researchers (Y. Kihara, Y. Kita, S. Ishii, unpublished data) measured multiple eicosanoids (PGs, LTs, and their metabolites) in animal models of MS. In the spinal cord, there was an obvious and dramatic shift from 5-lipoxygenase-dependent pathways to Cox-dependent pathways during the induction phase of disease progression. PAF was produced in the later phase of the disease. These results were in agreement with previous results demonstrating that PAF is not involved in the early T-cell dependent phase of the disease, but in the late phase, when macrophages or microglia are involved in disease progression (146) . Thus, lipid profiling can be used to predict which eicosanoids will be involved in disease induction, and which ones will be involved in protecting against disease. This type of predictive power can be used to guide more definitive studies using knockout mice, and the use of specific inhibitors, receptor agonists, or antagonists at various stages of disease.
CONCLUSION
Herein I present a summary of the enzymes and receptors involved in lipid mediator synthesis and function, with an emphasis on eicosanoids and PAF. Eicosanoids and PAF are produced from membrane phospholipids by the action of PLA2, in particular, cPLA2α. Polyunsaturated fatty Production of lipid mediators during deacylation-reacylation cycle (Lands' cycle). acids and lysophospholipids are further metabolized into a variety of bioactive compounds, collectively termed lipid mediators. Unmetabolized lysophospholipids are incorporated into membrane phospholipids, by the actions of acyltransferases using polyunsaturated fatty acyl-CoA. Thus, the production of lipid mediators is tightly coupled to the Lands' cycle (Figure 7) . Lipid mediators exert their functions through cognate GPCRs and the intracellular second messenger systems of individual cells and tissues. In concert with the actions of cytokines, neurotransmitters, hormones, and growth factors, lipid mediators play fundamental roles in maintaining healthy living systems. However, either excess or dysfunctions of the enzymes and/or receptors of lipid mediators can cause inflammatory and immune disorders, including bronchial asthma, rheumatoid arthritis, pulmonary fibrosis, MS, etc. Lipid mediators and their receptors are potentially important and novel therapeutic targets for various human diseases. Thus, although mouse models differ in many ways from human diseases, genetic knockout studies are a valuable tool for predicting both promising and adverse effects of drugs targeted for human use.
SUMMARY POINTS
1. Lipids have at least four major functions in the body: membrane components, an energy source, post-translational protein modification moieties, and autacoid lipid mediators.
2. Prostaglandins, leukotrienes (eicosanoids), and PAF are produced by enzymatic cascades initiated by Ca 2+ -dependent cPLA2.
3. Lysophospholipids are converted into various lipid mediators, or transformed into phospholipids by the recently identified acyltransferase superfamily.
4. Lipid mediators bind and activate GPCRs, and some have been reported to act on nuclear receptors as well.
5. Knockout mice in which the enzyme(s) or receptor(s) of lipid mediator synthesis and function are targeted exhibit a variety of physiological and pathological phenotypes.
6. To understand the molecular mechanisms of the cPLA2α-null phenotypes, we have established a comprehensive high throughput method of quantifying lipid mediators using LC-MS/MS.
7. Enzymes and receptors are therapeutic targets for various inflammatory and immune diseases.
FUTURE ISSUES
1. It is necessary to determine the biological significance of membrane diversity and asymmetry (saturated at sn-1 vs unsatutated at sn-2).
2. The mechanism of coordinated regulation and intracellular coupling of multiple enzyme systems by the putative scaffold systems must be examined.
3. Identification of specific and nonspecific transporters of lipid mediators is necessary.
4. The link between second messenger systems (Ca 2+ , cyclic nucleotide, etc) and cellspecific functions and phenotypes needs to be established.
Researchers need to develop specific enzyme inhibitors and receptor agonists and
antagonists.
